Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
H. Lee Moffitt Cancer Center and Research Institute
Vanderbilt-Ingram Cancer Center
Rutgers, The State University of New Jersey
AIO-Studien-gGmbH
Wake Forest University Health Sciences
Centre hospitalier de l'Université de Montréal (CHUM)
Memorial Sloan Kettering Cancer Center
University of California, Davis
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Vanderbilt-Ingram Cancer Center